Hepatobiliary Neoplasm
12
0
0
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
25.0%
3 terminated out of 12 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (12)
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
Nutritional Support for Patients Operated for Malignant Tumors in HPD Zone
Holographic Augmented Reality Versus Screen Visualisation of 3D Rendering Models for the Pre-operative Evaluation and Planning of Liver Resections
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
Immersive Virtual Reality Environment for Complex Cognitive Skills Curricular Training in Liver Surgery
Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer
Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses
Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
Permission to Collect Blood Over Time for Research
B-Receptor Signaling in Cardiomyopathy